Department of Pharmaceutical & Biomedical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA.
Mol Cancer Res. 2011 Nov;9(11):1509-19. doi: 10.1158/1541-7786.MCR-11-0336. Epub 2011 Sep 6.
Sphingosine kinases (SK) regulate the balance between proapoptotic ceramides and mitogenic sphingosine-1-phosphate (S1P); however, the functions of the two isoenzymes (SK1 and SK2) in tumor cells are not well defined. Therefore, RNA interference was used to assess the individual roles of SK1 and SK2 in tumor cell sphingolipid metabolism, proliferation, and migration/invasion. Treatment of A498, Caki-1, or MDA-MB-231 cells with siRNAs specific for SK1 or SK2 effectively suppressed the expression of the target mRNA and protein. Ablation of SK1 did not affect mRNA or protein levels of SK2 and reduced intracellular levels of S1P while elevating ceramide levels. In contrast, ablation of SK2 elevated mRNA, protein, and activity levels of SK1 and increased cellular S1P levels. Interestingly, cell proliferation and migration/invasion were suppressed more by SK2-selective ablation than by SK1-selective ablation, showing that the increased S1P does not rescue these phenotypes. Similarly, exogenous S1P did not rescue the cells from the antiproliferative or antimigratory effects of the siRNAs. Consistent with these results, differential effects of SK1- and SK2-selective siRNAs on signaling proteins, including p53, p21, ERK1, ERK2, FAK, and VCAM1, indicate that SK1 and SK2 have only partially overlapping functions in tumor cells. Overall, these data indicate that loss of SK2 has stronger anticancer effects than does suppression of SK1. Consequently, selective inhibitors of SK2 may provide optimal targeting of this pathway in cancer chemotherapy.
鞘氨醇激酶(SK)调节促凋亡神经酰胺和有丝分裂原鞘氨醇-1-磷酸(S1P)之间的平衡;然而,两种同工酶(SK1 和 SK2)在肿瘤细胞中的功能尚未明确。因此,使用 RNA 干扰来评估 SK1 和 SK2 在肿瘤细胞鞘脂代谢、增殖和迁移/侵袭中的个体作用。用针对 SK1 或 SK2 的 siRNA 处理 A498、Caki-1 或 MDA-MB-231 细胞,可有效抑制靶 mRNA 和蛋白的表达。抑制 SK1 不影响 SK2 的 mRNA 或蛋白水平,并降低细胞内 S1P 水平,同时升高神经酰胺水平。相反,抑制 SK2 会升高 SK1 的 mRNA、蛋白和活性水平,并增加细胞内 S1P 水平。有趣的是,SK2 选择性消融比 SK1 选择性消融更能抑制细胞增殖和迁移/侵袭,表明增加的 S1P 不能挽救这些表型。同样,外源性 S1P 不能挽救细胞免受 siRNA 的抗增殖或抗迁移作用。与这些结果一致,SK1 和 SK2 选择性 siRNA 对信号蛋白(包括 p53、p21、ERK1、ERK2、FAK 和 VCAM1)的差异影响表明,SK1 和 SK2 在肿瘤细胞中仅有部分重叠的功能。总的来说,这些数据表明,抑制 SK2 的缺失比抑制 SK1 的缺失具有更强的抗癌作用。因此,选择性 SK2 抑制剂可能为癌症化疗中靶向该途径提供最佳选择。